Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated (INSM) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 41.19 M | 721.62 M | 1.66 B | 1.33 B | 929.06 M |
| 2022 | 29.71 M | 103.83 M | 1.57 B | 1.66 B | 1.27 B |
| 2021 | 24.35 M | -104,514,000 | 833.04 M | 1.24 B | 837.04 M |
| 2020 | 16.56 M | -127,914,000 | 520.27 M | 796.16 M | 622.89 M |
| 2019 | 19.23 M | -90,391,000 | 480.63 M | 742.3 M | 555.19 M |